Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 580 | P/E | - | EPS this Y | 45.30% | Ern Qtrly Grth | - |
| Income | -133.91M | Forward P/E | 0.00 | EPS next Y | 46.30% | 50D Avg Chg | -100.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -100.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | 4.00 | Quick Ratio | 4.74 | Shares Outstanding | 58.03M | 52W Low Chg | - |
| Insider Own | 8.01% | ROA | -60.11% | Shares Float | 49.20M | Beta | 0.06 |
| Inst Own | 31.45% | ROE | - | Shares Shorted/Prior | 10.53M/14M | Price | 0.00001 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 296,298 | Target Price | - |
| Oper. Margin | - | Earnings Date | Aug 7 | Volume | 2,307,577 | Change | 0.00% |
About Tricida, Inc.
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.